Efficacy and safety of crizotinib plus bevacizumab in ALK/ROS-1/c-MET positive non-small cell lung cancer: an open-label, single-arm, prospective observational study

Background: Crizotinib is a tyrosine kinase inhibitor (TKI) effective in ALK/ROS-1/c-MET positive non-small cell lung cancer (NSCLC) patients. Bevacizumab is an antiangiogenic monoclonal antibody, and improves clinical benefit of NSCLC in combination with EGFR-TKIs or chemotherapy. However, the effi...

Полное описание

Сохранить в:
Библиографические подробности
Опубликовано в: :Am J Transl Res
Главные авторы: Huang, Ziwei, Xiong, Qi, Cui, Zhi, Tao, Haitao, Zhang, Sujie, Wang, Lijie, Cui, Pengfei, Chen, Shixue, Huang, Di, Yang, Bo, Hu, Yi
Формат: Artigo
Язык:Inglês
Опубликовано: e-Century Publishing Corporation 2021
Предметы:
Original Article
Online-ссылка:https://ncbi.nlm.nih.gov/pmc/articles/PMC8014364/
https://ncbi.nlm.nih.gov/pubmed/33841676
Метки: Добавить метку
Нет меток, Требуется 1-ая метка записи!

Схожие документы